U.S. patent application number 15/855492 was filed with the patent office on 2018-07-05 for methods for producing aripiprazole suspension and freeze-dried formulation.
The applicant listed for this patent is Otsuka Pharmaceutical Co., Ltd.. Invention is credited to Junichi Hatanaka, Shogo Hiraoka, Takakuni Matsuda.
Application Number | 20180185358 15/855492 |
Document ID | / |
Family ID | 39816777 |
Filed Date | 2018-07-05 |
United States Patent
Application |
20180185358 |
Kind Code |
A1 |
Hiraoka; Shogo ; et
al. |
July 5, 2018 |
METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED
FORMULATION
Abstract
Disclosed are a method for producing an aripiprazole suspension,
wherein the aripiprazole has a mean particle size of 1 to 10 ?m,
the method comprising the steps of: (a) combining bulk aripiprazole
and a vehicle to form a primary suspension; (b) subjecting the
primary suspension to first pulverization using e.g., a high shear
pulverizing machine, a dispersion machine that applies shear force
to a material to be processed, a colloid mill, an ultrasonic
dispersion machine, or a high-pressure jet type emulsifying
dispersion machine to form a secondary suspension; and (c)
subjecting the secondary suspension to second pulverization using
e.g., a high-pressure jet type emulsifying dispersion machine to
form a sterile final suspension; and a method for producing a
freeze-dried formulation from the aripiprazole suspension.
Inventors: |
Hiraoka; Shogo; (Osaka-shi,
JP) ; Matsuda; Takakuni; (Osaka-shi, JP) ;
Hatanaka; Junichi; (Osaka-shi, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Otsuka Pharmaceutical Co., Ltd. |
Tokyo |
|
JP |
|
|
Family ID: |
39816777 |
Appl. No.: |
15/855492 |
Filed: |
December 27, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15242843 |
Aug 22, 2016 |
|
|
|
15855492 |
|
|
|
|
12670352 |
Apr 23, 2010 |
9457026 |
|
|
PCT/JP2008/064076 |
Jul 30, 2008 |
|
|
|
15242843 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/496 20130101;
A61K 9/19 20130101; A61K 9/10 20130101; A61K 47/38 20130101; A61K
47/32 20130101; A61P 25/18 20180101; A61P 25/24 20180101; A61K
47/26 20130101 |
International
Class: |
A61K 31/496 20060101
A61K031/496; A61K 47/32 20060101 A61K047/32; A61K 9/10 20060101
A61K009/10; A61K 47/38 20060101 A61K047/38; A61K 9/19 20060101
A61K009/19; A61K 47/26 20060101 A61K047/26 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 31, 2007 |
JP |
2007-200088 |
Claims
1-23. (canceled)
24. A method for producing a freeze-dried formulation of
Aripiprazole Hydrate A, the method comprising the steps of: (a)
combining bulk aripiprazole and a vehicle to form a primary
suspension; (b) subjecting the primary suspension to first
pulverization to form a secondary suspension; (c) subjecting the
secondary suspension to second pulverization to form a final
suspension; (d) cooling the final suspension containing
Aripiprazole Hydrate A, to -20 to -55.degree. C. to freeze the
suspension; and subsequently performing drying at below about
0.degree. C.
25. A method for producing a freeze-dried formulation containing
aripiprazole in anhydrous form, the method comprising the steps of:
(a) combining bulk aripiprazole and a vehicle to form a primary
suspension; (b) subjecting the primary suspension to first
pulverization to form a secondary suspension; (c) subjecting the
secondary suspension to second pulverization to form a final
suspension; (d) cooling the final aripiprazole suspension using
bulk aripiprazole in the form of a monohydrate or anhydrous
crystals to -20 to -55.degree. C. to freeze the suspension; (e)
performing primary drying at below about 0.degree. C.; and (f)
performing secondary drying at above about 0.degree. C.
26. The method according to claim 24 wherein in the first
pulverization of step (b), the secondary suspension is formed by
pulverizing the primary suspension using a high shear pulverizing
machine, a dispersion machine that applies shear force to a
material to be processed, a colloid mill, an ultrasonic dispersion
machine, or a high-pressure jet type emulsifying dispersion
machine, and in the second pulverization of step (c), the final
suspension is formed by pulverizing the secondary suspension using
a high-pressure jet type emulsifying dispersion machine.
27. The method according to claim 24, wherein in the first
pulverization of step (b), the secondary suspension is formed by
pulverizing the primary suspension using a high shear pulverizing
machine or a dispersion machine that applies shear force to a
material to be processed, and in the second pulverization of step
(c), the final suspension is formed by pulverizing the secondary
suspension using a high-pressure homogenizer.
28. The method according to claim 27, wherein in step (c), the
high-pressure homogenizer is used at a pulverization pressure of
300 to 1000 bar.
29. The method according to claim 27, wherein in step (c), the
high-pressure homogenizer is used at a pulverization pressure of
300 to 600 bar.
30. The method according to claim 27, wherein in step (c), the
high-pressure homogenizer is used at an inlet temperature of 1 to
70.degree. C.
31. The method according to claim 24, wherein in the first
pulverization of step (b), the secondary suspension is formed by
pulverizing the primary suspension using a high-pressure
homogenizer, and in the second pulverization of step (c), the final
suspension is formed by pulverizing the secondary suspension using
a high-pressure homogenizer.
32. The method according to claim 31, wherein in the first
pulverization of step (b), the secondary suspension is formed by
pulverizing the primary suspension using a high-pressure
homogenizer at a pulverization pressure of 50 to 200 bar, and in
the second pulverization of step (c), the final suspension is
formed by pulverizing the secondary suspension using a
high-pressure homogenizer at a pulverization pressure of 200 to
1000 bar, wherein the difference between the pulverization pressure
in step (b) and the pulverization pressure in step (c) is 100 to
900 bar.
33. The method according to claim 32, wherein in step (b), the
pulverization pressure of the high-pressure homogenizer is in the
range of 50 to 200 bar, and in step (c), the pulverization is
carried out plural times and the pulverization pressure is raised
stepwise within the range of 200 to 1000 bar.
34. The method according to claim 33, wherein in step (c), the
final pulverization pressure of the high-pressure homogenizer is
300 to 600 bar.
35. The method according to claim 31, wherein in steps (b) and (c),
the high-pressure homogenizer is used at an inlet temperature of 1
to 50.degree. C.
36. The method according to claim 24, wherein the vehicle contains
at least one suspending agent selected from the group consisting of
carboxymethyl cellulose, carboxymethyl celllose salts,
hydroxypropyl cellulose, hydroxypropylethyl cellulose,
hydroxypropylmethyl cellulose and polyvinyl pyrrolidone.
37. The method according to claim 24, wherein the bulk aripiprazole
contains aripiprazole particles with a particle size of 100 .mu.m
or more in an amount of 10% or more, and has a mean particle size
of 20 .mu.m to 1000 .mu.m.
38. The method according to claim 24, wherein the bulk aripiprazole
has a mean particle size of more than 100 .mu.m.
39. The method according to claim 24, wherein the bulk aripiprazole
has a mean particle size of 110 .mu.m to 1000 .mu.m.
40. The method according to claim 24, wherein the aripiprazole in
the aripiprazole suspension has a mean particle size of 1 to 10
.mu.m.
41. A method for producing an aripiprazole suspension comprising
the steps of: (a) combining bulk aripiprazole and a vehicle to form
a primary suspension, wherein the bulk aripiprazole is in the form
selected from the group consisting of Anhydride Crystals B,
Anhydride Crystals C, Anhydride Crystals D, Anhydride, Crystals E,
Anhydride Crystals F, and Anhydride Crystals G; (b) subjecting the
primary suspension to first pulverization to form a secondary
suspension; and (c) subjecting the secondary suspension to second
pulverization to form a final suspension.
42. A method for producing a freeze-dried formulation of
Aripiprazole Hydrate A, the method comprising the steps of: (1)
cooling the suspension produced by the method according to claims
41 to -20 to -55.degree. C. to freeze the suspension; and
subsequently performing drying at below about 0.degree. C.
43. A method for producing a freeze-dried formulation containing
aripiprazole in anhydrous form, the method comprising the steps of:
(1) cooling the aripiprazole suspension produced by the method
according to claims 41 to -20 to -55.degree. C. to freeze the
suspension; (2) performing primary drying at below about 0.degree.
C.; and (3) performing secondary drying at above about 0.degree. C.
Description
TECHNICAL FIELD
[0001] The present invention relates to a method for producing an
aripiprazole suspension, and also a method for producing
freeze-dried formulations.
BACKGROUND ART
[0002] Aripiprazole is a drug commonly known as an atypical
antipsychotic agent. Using an aripiprazole aqueous suspension as an
injectable formulation has been proposed for the administration of
aripiprazole. In particular, a suspension obtained by suspending
aripiprazole with a mean particle size of about 1 to about 10 .mu.m
in an aqueous vehicle is known to have excellent sustained-release
properties and bioavailability (Patent Document 3).
[0003] In prior art, aseptic pulverization of bulk aripiprazole was
difficult at the commercial production level. For example, a ball
milling method, which uses ceramic beads widely used in wet
milling, has problems: bead friction may cause contamination;
additionally, ball mills capable of in-line sterilization are
generally not commercially available currently.
[0004] Moreover, the ball mill pulverization method may possibly
involve a problem of short-pass in which some large particles
possibly slip through the beads. As shown in Patent Document 4, it
is preferable to use bulk aripiprazole having a desired small
particle size, preferably having a mean particle size of about 100
.mu.m or less, more preferably about 95% of the crystals having a
particle size less than 100 .mu.m with a narrow particle size
distribution. However, production of such bulk aripiprazole having
a mean particle size of about 100 .mu.m or less requires particular
crystallization techniques like an impinging jet crystallization
method, as described in Patent Document 4.
[0005] On the other hand, particle size reduction can be carried
out using a high-pressure homogenizer; however, when a 10%
suspension of aripiprazole having a mean particle size of more than
100 .mu.m is pulverized with a high-pressure homogenizer, clogging
occurs in the line, precluding pulverization. Therefore, it is
desired to use aripiprazole preferably with a mean particle size of
100 .mu.m or less.
[0006] However, suspending such aripiprazole with a mean particle
size of about 100 .mu.m or less in a vehicle solution is
accompanied by foaming. Therefore, mixing under vacuum is necessary
for the preparation of a homogeneous suspension (see Patent
Document 3, Example 1 and paragraph 0089).
[0007] When mixing is carried out under vacuum, outside air may be
introduced, which requires measures to prevent contamination from
the external environment. Improvement in this aspect is
desired.
[0008] Patent Document 1 discloses a method for preparing small
particles containing a poorly water-soluble drug, comprising the
steps of:
[0009] (a) mixing at high shear an admixture of a poorly
water-soluble drug and one or more surface active substances in an
aqueous carrier in the absence of an organic solvent within a first
temperature range at or above the melting point of the poorly
water-soluble drug to form a heated suspension containing the drug
wherein the drug is molten;
[0010] (b) homogenizing the heated suspension in a first pressure
range and within the first temperature range to form a heated
homogenate containing the drug wherein the drug is molten;
[0011] (c) cooling the heated homogenate to a second temperature
range below the melting temperature of the poorly water-soluble
drug to form a transiently stable, cooled homogenate containing the
drug;
[0012] (d) applying a particle stabilizing energetic process to the
cooled homogenate within a second temperature range below the
melting point of the drug and in a second pressure range to form a
cooled dispersion of stabilized small particles containing the
drug; and
[0013] (e) drying the cooled dispersion to form dried small
particles containing the poorly water-soluble drug.
[0014] However, in the method of Patent Document 1, preparation of
an emulsion heated at a temperature higher than the melting point
of the drug is essential, and there is a problem in maintaining the
crystal form.
[0015] Patent Document 2 discloses effective solubilization or
dispersion means of poorly soluble compounds by adding a
combination of a predetermined amount of an oily component (fat),
an emulsifier, and cyclodextrin. It teaches that a homomixer is
used for coarse emulsification, and that a high-pressure
homogenizer or an ultrasonic homogenizer is used for fine
emulsification. However, in Patent Document 2, the composition
containing a poorly soluble compound that is solubilized or
dispersed takes the form of a fat emulsion, and not an aqueous
suspension.
[0016] Patent Document 3 discloses a method for preparing a sterile
freeze-dried formulation comprising the steps of:
[0017] (a) preparing sterile bulk aripiprazole having a desired
particle size distribution;
[0018] (b) preparing a sterile vehicle for the sterile bulk
aripiprazole;
[0019] (c) combining the sterile aripiprazole and the sterile
vehicle to form a sterile primary suspension that includes a
sterile mixture of solids;
[0020] (d) reducing the mean particle size of the sterile mixture
of solids in the sterile primary suspension, e.g., by an aseptic
wet milling to within the range from about 1 to about 100 .mu.m,
particularly about 1 to 10 .mu.m, to form a sterile final
suspension; and
[0021] (e) freeze-drying the sterile final suspension to form the
freeze-dried formulation.
It teaches that wet ball milling is preferred as the aseptic wet
milling procedure in step (d).
[0022] Non-Patent Document 1 discloses that microfluidizers have
two advantages over other methods of decreasing a mean particle
size: the final products have no contaminants, and production is
easily scaled up. [0023] Patent Document 1: Japanese Unexamined
Patent Publication No. 2003-531162 [0024] Patent Document 2:
Japanese Unexamined Patent Publication No. 2005-22989 [0025] Patent
Document 3: Japanese Unexamined Patent Publication No. 2007-509148
[0026] Patent Document 4: Japanese Unexamined Patent Publication
No. 2007-509153 [0027] Patent Document 5: Japanese Patent No.
3760264 [0028] Patent Document 6: Japanese Patent No. 3750023
[0029] Non-Patent Document 1: Kathleen J. Illing, et al., "Use of
Microfluidizer Processing for Preparation of Pharmaceutical
Suspensions", Pharm. Tech., OCTOBER 1996, pages 78 to 88. [0030]
Non-Patent Document 2: "Study on Crystal Transformation of
Aripiprazole" Satoshi Aoki, et al., The Fourth Japan-Korea
Symposium on Separation Technology (October 6th-8th, 1996),
p.937-940
DISCLOSURE OF THE INVENTION
Problems to be Solved by the Invention
[0031] Suspensions prepared by suspending aripiprazole with a mean
particle size of about 1 to about 10 .mu.m in an aqueous vehicle
are known to have excellent sustained-release properties. Wet ball
milling of aripiprazole preferably having a mean particle size of
about 100 .mu.m or less, more preferably about 95% of the crystals
having a particle size of 100 .mu.m or less, is known as a process
for producing such aripiprazole suspensions with a mean particle
size of 1 to 10 .mu.m, as shown in Patent Documents 3 and 4.
[0032] However, production of bulk aripiprazole having a mean
particle size of about 100 .mu.m or less required special methods,
such as an impinging jet crystallization method, for producing a
bulk drug. During the step of suspending the bulk aripiprazole
having a mean particle size of about 100 .mu.m or less in a
vehicle, mixing under vacuum was necessary.
[0033] For this reason, a production method has been desired that
can use bulk powder containing aripiprazole particles with a
particle size of 100 .mu.m or more in an amount of 10% or more,
preferably bulk powder with a mean particle size of more than 100
.mu.m, particularly about 110 .mu.m to 1000 .mu.m, more preferably
200 .mu.m to 400 .mu.m, produced by batch crystallization, without
the need for vacuum mixing.
[0034] Moreover, the wet ball milling method has drawbacks: bead
friction may possibly cause contamination, and ball mills capable
of in-line sterilization are currently not commercially available.
Therefore, a method that rarely induces contamination and uses a
production apparatus capable of in-line sterilization has been
desired.
Means for Solving the Problems
[0035] The present inventors found that even when using bulk
aripiprazole containing 10% or more of aripiprazole particles with
a particle size of 100 .mu.m or more and having a mean particle
size of 20 to 1000 .mu.m, preferably bulk aripiprazole having a
mean particle size of more than 100 .mu.m, particularly preferably
110 .mu.m to 1000 .mu.m, most preferably 200 .mu.m to 400 .mu.m,
the above problems can be solved by performing a first
pulverization step using a high shear pulverizing machine such as a
high shear homomixer, a dispersion machine that applies shear force
to a material to be processed, a colloid mill, an ultrasonic
dispersion machine, or a high-pressure jet type emulsifying
dispersion machine such as a high-pressure homogenizer; and further
performing a second pulverization step using a high-pressure jet
type emulsifying dispersion machine such as a high-pressure
homogenizer.
[0036] The present invention has been accomplished based on these
findings and further research, and provides the following
production method:
[0037] Item 1: A method for producing an aripiprazole suspension
comprising the steps of:
[0038] (a) combining bulk aripiprazole and a vehicle to form a
primary suspension;
[0039] (b) subjecting the primary suspension to first pulverization
to form a secondary suspension; and
[0040] (c) subjecting the secondary suspension to second
pulverization to form a final suspension.
[0041] Item 2: The method according to Item 1, wherein in the first
pulverization of step (b), the secondary suspension is formed by
pulverizing the primary suspension using a high shear pulverizing
machine, a dispersion machine that applies shear force to a
material to be processed, a colloid mill, an ultrasonic dispersion
machine, or a high-pressure jet type emulsifying dispersion
machine, and in the second pulverization of step (c), the final
suspension is formed by pulverizing the secondary suspension using
a high-pressure jet type emulsifying dispersion machine.
[0042] Item 3: The method according to Item 1 or 2, wherein in the
first pulverization of step (b), the secondary suspension is formed
by pulverizing the primary suspension using a high shear
pulverizing machine or a dispersion machine that applies shear
force to a material to be processed, and in the second
pulverization of step (c), the final suspension is formed by
pulverizing the secondary suspension using a high-pressure
homogenizer.
[0043] Item 4: The method according to Item 3, wherein in step (c),
the high-pressure homogenizer is used at a pulverization pressure
of 300 to 1000 bar.
[0044] Item 5: The method according to Item 3 or 4, wherein in step
(c), the high-pressure homogenizer is used at a pulverization
pressure of 300 to 600 bar.
[0045] Item 6: The method according to any of Items 3 to 5, wherein
in step (c), the high-pressure homogenizer is used at an inlet
temperature of 1 to 70.degree. C.
[0046] Item 7: The method according to Item 1 or 2, wherein in the
first pulverization of step (b), the secondary suspension is formed
by pulverizing the primary suspension using a high-pressure
homogenizer, and in the second pulverization of step (c), the final
suspension is formed by pulverizing the secondary suspension using
a high-pressure homogenizer.
[0047] Item 8: The method according to Item 1, 2, or 7 wherein in
the first pulverization of step (b), the secondary suspension is
formed by pulverizing the primary suspension using the
high-pressure homogenizer at a pulverization pressure of 50 to 200
bar, and in the second pulverization of step (c), the final
suspension is formed by pulverizing the secondary suspension using
a high-pressure homogenizer at a pulverization pressure of 200 to
1000 bar, wherein the difference between the pulverization pressure
in step (b) and the pulverization pressure in (c) is 100 to 900
bar.
[0048] Item 9: The method according to Item 8, wherein in step (b),
the pulverization pressure of the high-pressure homogenizer is in
the range of 50 to 200 bar, and in step (c), the pulverization is
carried out plural times and the pulverization pressure is raised
stepwise within the range of 200 to 1000 bar.
[0049] Item 10: The method according to Item 9, wherein in step
(c), the final pulverization pressure of the high-pressure
homogenizer is 300 to 600 bar.
[0050] Item 11: The method according to any one of Items 7 to 10,
wherein in steps (b) and (c), the high-pressure homogenizer is used
at an inlet temperature of 1 to 50.degree. C.
[0051] Item 12: The method according to any one of Items 1 to 11,
wherein the vehicle contains at least one suspending agent selected
from the group consisting of carboxymethyl cellulose, carboxymethyl
cellulose salts, hydroxypropyl cellulose, hydroxypropylethyl
cellulose, hydroxypropylmethyl cellulose and polyvinyl
pyrrolidone.
[0052] Item 13: The method according to any one of Items 1 to 12,
wherein the bulk aripiprazole contains 10% or more of aripiprazole
particles with a particle size of 100 .mu.m or more, and has a mean
particle size of 20 .mu.m to 1000 .mu.m.
[0053] Item 14: The method according to any one of Items 1 to 13,
wherein the bulk aripiprazole has a mean particle size of more than
100 .mu.m.
[0054] Item 15: The method according to any one of Items 1 to 14,
wherein the bulk aripiprazole has a mean particle size of 110 .mu.m
to 1000 .mu.m.
[0055] Item 16: The method according to any one of Items 1 to 15,
wherein the bulk aripiprazole has a mean particle size of 200 .mu.m
to 400 .mu.m.
[0056] Item 17: The method according to any one of Items 1 to 16,
wherein the aripiprazole in the aripiprazole suspension has a mean
particle size of 1 to 10 .mu.m.
[0057] Item 18: The method according to any one of Items 1 to 17,
wherein the aripiprazole in the aripiprazole suspension has a mean
particle size of 1 to 5 .mu.m.
[0058] Item 19: The method according to any one of Items 1 to 18,
wherein the aripiprazole in the aripiprazole suspension has a mean
particle size of 2 to 4 .mu.m.
[0059] Item 20: The method according to any one of Items 1 to 19,
wherein the aripiprazole in the aripiprazole suspension has a mean
particle size of 2 to 3 .mu.m.
[0060] Item 21: The method according to any one of Items 1 to 6,
comprising the steps of:
[0061] (I) combining sterile bulk aripiprazole with a mean particle
size of 200 .mu.m to 400 .mu.m and a sterile vehicle (preferably a
sterile vehicle containing carboxymethyl cellulose sodium salt) to
form a sterile primary suspension;
[0062] (II) subjecting the sterile primary suspension to first
pulverization using a high shear pulverizing machine or a
dispersion machine that applies shear force to a material to be
processed to form a sterile secondary supension; and
[0063] (III) subjecting the sterile secondary suspension to second
pulverization using a high-pressure homogenizer to form a sterile
final suspension;
wherein the aripiprazole in the sterile final suspension (namely,
the desired sterile aripiprazole suspension) has a mean particle
size of 1 to 10 .mu.m (preferably 1 to 5 .mu.m, particularly 2 to 4
.mu.m).
[0064] Item 22: The method according to any one of Items 1 to 21,
wherein the bulk aripiprazole is in the form selected from the
group consisting of monohydrate and Anhydride Crystals B.
[0065] Item 23: The method according to any one of Items 1 to 22,
further comprising the step of filtering the final suspension with
a filter having a nominal filtration rating of 10 to 225 .mu.m.
[0066] Item 24: A method for producing a freeze-dried formulation
of Aripiprazole Hydrate A, the method comprising the steps of:
cooling the suspension produced by the method according to any one
of Items 1 to 23 and containing Aripiprazole Hydrate A to -20 to
-55.degree. C. to freeze the suspension; and subsequently
performing drying at a temperature lower than about 0.degree.
C.
[0067] Item 25: A method for producing a freeze-dried formulation
containing aripiprazole in anhydrous form, the method comprising
the following three steps of:
[0068] (1) cooling the aripiprazole suspension produced by the
method according to any one of Items 1 to 23 using bulk
aripiprazole in the form of a monohydrate or anhydrous crystals to
-20 to -55.degree. C. to freeze the suspension;
[0069] (2) performing primary drying at a temperature lower than
about 0.degree. C.; and
[0070] (3) performing secondary, drying at a temperature higher
than about 0.degree. C.
Effects of the Invention
[0071] The present invention provides excellent effects as
described below.
[0072] (a) The method for producing an aripiprazole suspension
according to the present invention, which comprises two-step
pulverization of bulk aripiprazole, is particularly effective when
using bulk aripiprazole containing at least 10% of aripiprazole
particles having a particle size of 100 .mu.m or more and having a
mean particle size of 20 .mu.m to 1000 .mu.m, preferably bulk
aripiprazole having a mean particle size of more than 100 .mu.m,
particularly 110 .mu.m to 1000 .mu.m, most preferably 200 .mu.m to
400 .mu.m. However, regardless of the mean particle size, the
method of the present invention readily produces an aripiprazole
suspension having a mean particle size of 1 to 10 .mu.m, preferably
1 to 5 .mu.m, more preferably 2 to 4 .mu.m, and most preferably 2
to 3 .mu.m.
[0073] (b) By carrying out two-step pulverization, in accordance
with the present invention, i.e., a first pulverization step using
a high shear pulverizing machine (e.g., a high shear homomixer), a
dispersion machine that applies shear force to a material to be
processed, a colloid mill, an ultrasonic dispersion machine, or a
high-pressure jet type dispersion machine (e.g., a high-pressure
homogenizer), and a second pulverization step using a high-pressure
jet type dispersion machine (e.g., a high-pressure homogenizer), an
aripiprazole suspension having a mean particle size of 1 to 10
.mu.m can be prepared, even using bulk powder with a large mean
particle size, particularly bulk aripiprazole with a mean particle
size of more than 100 .mu.m obtained by batch crystallization, etc.
Therefore, unlike Patent Document 4, special crystallization
techniques like an impinging jet crystallization method are
unnecessary for the preparation of bulk aripiprazole.
[0074] (c) The method of the invention uses, as sterile bulk
aripiprazole, the bulk aripiprazole containing at least 10% of
aripiprazole particles having a particle size of 100 .mu.m or more
and having a mean particle size of 20 .mu.m to 1000 .mu.m,
preferably bulk aripiprazole having a mean particle size of more
than 100 .mu.m, particularly 110 .mu.m to 1000 .mu.m, and most
preferably 200 .mu.m to 400 .mu.m, and therefore the step of
combining bulk aripiprazole and a vehicle, the first pulverization
step and the second pulverization step can be performed without
adopting a vacuum mixing process as used in Patent Document 3. This
eliminates the possibility of outside air mixing with the
formulation during production of the sterile formulation, providing
great advantages for a method for producing sterile products.
[0075] (d) Moreover, since no wear occurs as in a ball mill, there
are no contamination problems caused by such wear.
[0076] (e) Short pass of large particles, which is a problem in wet
ball milling, is less likely to occur, and therefore a homogeneous
suspension free of coarse aripiprazole particles is obtained. As a
result, the Aripiprazole suspension can be filtered with a smaller
pore size for removing foreign substances after pulverization, and
is advantageous from the standpoint of foreign substance
control.
[0077] (f) In commercial scale aseptic production, clean-in-place
(CIP) and sterilization-in-place (SIP) are difficult with respect
to apparatuses such as ball mills; however, the production
apparatus used in the pulverization method (first pulverization
step and second pulverization step) of the invention allows for CIP
and SIP. Hence, the apparatus is easily kept sterile by in-line
sterilization.
[0078] (g) When carboxymethyl cellulose or a salt thereof is
selected as a suspending agent for a vehicle in the present
production method, it is possible to avoid excessive pulverization
in which the mean particle size falls below 1 .mu.m.
Best Mode for Carrying out the Invention
[0079] The production method of the present invention is described
in detail below.
[0080] In the present invention, the term "mean particle size"
refers to volume mean diameter as measured by laser-light
scattering (LLS) methods. Particle size distribution is measured by
LLS methods, and mean particle size is calculated from the particle
size distribution.
Bulk Aripiprazole
[0081] Aripiprazole has the structure
##STR00001##
and is an atypical antipsychotic agent useful in treating
schizophrenia. It has poor aqueous solubility (<1.mu.g/ml at
room temperature).
[0082] Aripiprazole bulk drug or bulk powder may have any mean
particle size and particle size distribution. Generally, it is
preferable to use bulk aripiprazole containing aripiprazole
particles having a particle size of 100 .mu.m or more in a
proportion of at least 10% and having a mean particle size of 20
.mu.m to 1000 .mu.m, preferably bulk aripiprazole having a mean
particle size of more than 100 .mu.m, particularly 110 .mu.m to
1000 .mu.m, and most preferably 200 .mu.m to 400 .mu.m.
[0083] Moreover, the crystal form of bulk aripiprazole is not
limited and various forms are usable. Examples of the crystal forms
of aripiprazole include monohydrate disclosed in Non-Patent
Document 2 (in the present specification, the term "a monohydrate"
as such means the monohydrate disclosed in Non-Patent Document 2),
Hydrate A and Anhydride Crystals B that are disclosed in Patent
Document 5, Anhydride Crystals C, Anhydride Crystals D, Anhydride
Crystals E, Anhydride Crystals F, and
[0084] Anhydride Crystals G that are disclosed in Patent Document
6. Among these, a monohydrate and Anhydride Crystals B are
preferable.
[0085] In the present invention, by using a monohydrate crystal
(Non-Patent Document 2) as bulk aripiprazole, a suspension of
Hydrate A (Patent Document 5) is obtained by the method of the
invention. Also, by using Hydrate A as bulk aripiprazole, a
suspension of Hydrate A can be obtained by the method of the
invention. Anhydride Crystals B (Patent Document 5), Anhydride
Crystals C, Anhydride Crystals D, Anhydride Crystals E, Anhydride
Crystals F, and Anhydride Crystals G (Patent Document 6) can also
be used as bulk aripiprazole. With these crystals, an aripiprazole
suspension in which Hydrate A and anhydrous aripiprazole are mixed
is obtained. Additionally, Anhydride Crystals B, Anhydride Crystals
C, Anhydride Crystals D, Anhydride Crystals E, Anhydride Crystals
F, or Anhydride Crystals G may be recrystallized from ethanol and
water, or the like in advance to thereby prepare a monohydrate, and
the resulting monohydrate may be used as bulk Aripiprazole.
Vehicle
[0086] The vehicle used in the invention generally includes:
[0087] (1) one or more suspending agents,
[0088] (2) water for injection,
[0089] (3) optionally one or more bulking agents or isotonic
agents,
[0090] (4) optionally one or more buffers, and
[0091] (5) optionally one or more pH adjusting agents.
[0092] The suspending agent will be present in an amount within the
range from about 0.2 to about 10% by weight, preferably about 0.3
to about 5% by weight, more preferably about 0.4 to about 0.9% by
weight, based on the total weight of the sterile injectable
formulation (the aripiprazole suspension of the invention).
Examples of suspending agents suitable for use include, but are not
limited to, one, two or more of the following: carboxymethyl
cellulose or a salt thereof (e.g., sodium carboxymethyl cellulose),
hydroxypropyl cellulose, hydroxypropylethyl cellulose,
hydroxypropylmethyl cellulose, and polyvinylpyrrolidone, with
carboxymethyl cellulose or a salt thereof, particularly sodium
salt, being preferred. Other suspending agents suitable for use in
the vehicle for the aripiprazole include various polymers, low
molecular weight oligomers, natural products, and surfactants,
including nonionic and ionic surfactants, such as cetyl pyridinium
chloride, gelatin, casein, lecithin (phosphatides), dextran,
glycerol, gum acacia, cholesterol, tragacanth, stearic acid,
benzalkonium chloride, calcium stearate, glycerol monostearate,
cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters,
polyoxyethylene alkyl ethers (e.g., macrogol ethers such as
cetomacrogol 1000), polyoxyethylene castor oil derivatives,
polyoxyethylene sorbitan fatty acid esters (e.g., the commercially
available Tweens (registered trademark); e.g., Tween 20 (registered
trademark) and Tween 80 (registered trademark) (ICI Specialty
Chemicals)); polyethylene glycols (e.g., Carbowaxs 3350 (registered
trademark) and 1450 (registered trademark), and Carbopol 934
(registered trademark) (Union Carbide)), dodecyl trimethyl ammonium
bromide, polyoxyethylene stearates, colloidal silicon dioxide,
phosphates, sodium dodecyl sulfate, carboxymethylcellulose calcium,
hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L),
methylcellulose, hydroxyethylcellulose,
hydroxypropylmethylcellulose, hydroxypropylmethyl-cellulose
phthalate, non-crystalline cellulose, magnesium aluminum silicate,
triethanolamine, polyvinyl alcohol (PVA),
4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and
formaldehyde (also known as tyloxapol, superione, and triton),
poloxamers (e.g., Pluronics F68 (registered trademark) and F108
(registered trademark), which are block copolymers of ethylene
oxide and propylene oxide); poloxamines (e.g., Tetronic 908
(registered trademark), also known as Poloxamine 908 (registered
trademark), which is a tetrafunctional block copolymer derived from
sequential addition of propylene oxide and ethylene oxide to
ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); a
charged phospholipid such as dimyristoyl phosphatidyl glycerol,
dioctylsulfosuccinate (DOSS); Tetronic 1508 (registered trademark)
(T-1508) (BASF Wyandotte Corporation), dialkylesters of sodium
sulfosuccinic acid (e.g., Aerosol OT (registered trademark), which
is a dioctyl ester of sodium sulfosuccinic acid (American
Cyanamid)); Duponol P (registered trademark), which is a sodium
lauryl sulfate (DuPont); Tritons X-200 (registered trademark),
which is an alkyl aryl polyether sulfonate (Rohm and Haas);
Crodestas F-110 (registered trademark), which is a mixture of
sucrose stearate and sucrose distearate (Croda Inc.);
p-isononylphenoxypoly-(glycidol), also known as Olin-10G
(registered trademark) or Surfactant 10-G (registered trademark)
(Olin Chemicals, Stamford, Conn.); Crodestas SL-40 (Croda, Inc.);
and SA9OHCO, which is C.sub.18H.sub.37CH.sub.2
(CON(CH.sub.3))--CH.sub.2(CHOH).sub.4(CH.sub.2OH).sub.2 (Eastman
Kodak Co.); decanoyl-N-methylglucamide; n-decyl
.beta.-D-glucopyranoside; n-decyl .beta.-D-maltopyranoside;
n-dodecyl .beta.-D-glucopyranoside; n-dodecyl .beta.-D-maltoside;
heptanoyl-N-methylglucamide; n-heptyl-.beta.-D-glucopyranoside;
n-heptyl .beta.-D-thioglucoside; n-hexyl .beta.-D-glucopyranoside;
nonanoyl-N-methylglucamide; n-nonyl .beta.-D-glucopyranoside;
octanoyl-N-methylglucamide; n-octyl-.beta.-D-glucopyranoside; octyl
.beta.-D-thioglucopyranoside; and the like.
[0093] Most of these suspending agents are known pharmaceutical
excipients, and are described in detail in the Handbook of
Pharmaceutical Excipients, published jointly by the American
Pharmaceutical Association and The Pharmaceutical Society of Great
Britain (The Pharmaceutical Press, 1986), specifically incorporated
by reference. The suspending agents are commercially available
and/or can be prepared by techniques known in the art.
[0094] In the invention, it is preferable to use carboxymethyl
cellulose or a salt thereof, hydroxypropyl cellulose,
hydroxypropylethyl cellulose, hydroxypropylmethyl cellulose, or
polyvinylpyrrolidone as a suspending agent for a vehicle. The use
of carboxymethyl cellulose (hereinafter occasionally referred to as
"CMC") or a salt thereof (preferably sodium salt (hereinafter
occasionally referred to as "CMCNa")) particularly ensures the
prevention of excessive pulverization in which the mean particle
size falls below 1 .mu.m, even when pulverization in the second
pulverization step is repeatedly performed or performed over a
prolonged period.
[0095] The viscosity range of carboxymethyl cellulose or the sodium
salt thereof may be suitably selected from a wide range. Generally,
the viscosity of a 4% aqueous solution at 25.degree. C. is
preferably about 20 to 400 cps, particularly about 50 to 200
cps.
[0096] If desired, the vehicle of the present invention may contain
bulking agent (also referred to as a cryogenic/lyophilize
protecting agent) or isotonic agent. The agent will be present in
an amount within the range from about 1 to about 10% by weight,
preferably from about 1.5 to about 8% by weight, more preferably
from about 2 to about 5% by weight, based on the total weight of
the sterile injectable formulation (the aripiprazole suspension of
the invention). Examples of bulking agents or isotonic agents
suitable for use herein include, but are not limited to, one, two
or more of the following: mannitol, sucrose, maltose, xylitol,
glucose, starches, sorbitol, and the like, with mannitol being
preferred for formulations where the mean particle size is about 1
micron or above.
[0097] As required, the vehicle of the present invention may
contain buffer. The buffer will be employed in an amount to adjust
the pH of an aqueous suspension of aripiprazole to from about 6 to
about 8, preferably about 7. To achieve such a pH, the buffer,
depending on the type, will usually be employed in an amount within
the range from about 0.02 to about 2% by weight, preferably from
about 0.03 to about 0.1% by weight, based on the total weight of
the sterile injectable formulation (the aripiprazole suspension of
the invention). Examples of buffers suitable for use herein
include, but are not limited to, one, two or more of the following:
sodium phosphate, potassium phosphate, or TRIS buffer, with sodium
phosphate being preferred.
[0098] The vehicle of the invention may optionally include a pH
adjusting agent that is employed in an amount to adjust the pH of
the aqueous suspension of aripiprazole within the range from about
6 to about 7.5, preferably about 7, and may be an acid or base
depending upon whether the pH of the aqueous suspension of the
freeze-dried aripiprazole needs to be raised or lowered to reach
the desired neutral pH of about 7. Thus, when the pH needs to be
lowered, an acidic pH adjusting agent such as hydrochloric acid or
acetic acid, preferably hydrochloric acid, may be employed. When
the pH needs to be raised, a basic pH adjusting agent such as
sodium hydroxide, potassium hydroxide, magnesium oxide or magnesium
hydroxide, preferably sodium hydroxide, will be employed.
Production Method of the Invention
[0099] The production method of the invention is described
below.
[0100] As described above, the present invention provides a method
for producing an aripiprazole suspension, the method comprising the
steps of:
[0101] (a) combining bulk aripiprazole and a vehicle to form a
primary suspension;
[0102] (b) subjecting the primary suspension to first pulverization
to form a secondary suspension; and
[0103] (c) subjecting the secondary suspension to second
pulverization to form a final suspension.
[0104] According to one preferred embodiment of the invention,
there is provided the following method: A method for producing a
sterile aripiprazole suspension in which aripiprazole has a mean
particle size of 1 to 10 .mu.m, preferably 1 to 5 .mu.m, more
preferably 2 to 4 .mu.m, most preferably about 2 to 3 .mu.m, the
method comprising the steps of:
[0105] (A) combining sterile bulk aripiprazole and a sterile
vehicle to form a sterile primary suspension;
[0106] (B) subjecting the sterile primary suspension to first
pulverization using a high shear pulverizing machine, a dispersion
machine that applies shear force to a material to be processed, a
colloid mill, an ultrasonic dispersion machine, or a high-pressure
jet type emulsifying dispersion machine, to form a sterile
secondary suspension; and
[0107] (C) subjecting the sterile secondary suspension to second
pulverization using a high-pressure jet type emulsifying dispersion
machine to form a sterile final suspension.
[0108] In carrying out the method for preparing the sterile
aripiprazole suspension of the invention, it is required that
everything be sterile so that sterile aripiprazole and a sterile
vehicle are combined aseptically to form a sterile suspension.
[0109] However, when it is possible to perform sterilization after
the desired aripiprazole suspension is obtained, the sterile
aripiprazole and the sterile vehicle need not necessarily be used
in the method including steps (A), (B) and (C) above.
(A) Step of Combining Sterile Bulk Aripiprazole and Sterile Vehicle
to Form a Sterile Primary Suspension
[0110] This step (A) comprises the following steps (A-1), (A-2) and
(A-3).
(A-1) Step of Preparing Sterile Bulk Aripiprazole
[0111] This step typically prepares sterile bulk aripiprazole
containing 10% or more of aripiprazole particles having a particle
size of 100 .mu.m or more and having a mean particle size of 20
.mu.m to 1000 .mu.m, preferably sterile bulk aripiprazole having a
mean particle size of more than 100 .mu.m, particularly preferably
110 .mu.m to 1000 .mu.m, most preferably 200 .mu.m to 400
.mu.m.
[0112] The method for sterilizing bulk aripiprazole is not limited,
and can be selected from a number of methods including aseptic
crystallization, autoclave sterilization, gas sterilization, and
radiation sterilization. Among them, aseptic crystallization is
preferred.
[0113] Aseptic crystallization is a process in which a solution
prepared by dissolving aripiprazole in a solvent is sterilized by
filtration sterilization etc., and then crystallization is carried
out. A number of such processes, such as a continuous
crystallization method or a batch crystallization method, can be
used without limitation.
[0114] Autoclave sterilization, gas sterilization, or radiation
sterilization may be conducted in accordance with conventional
methods that can sterilize aripiprazole.
[0115] The crystalline form of sterile aripiprazole is known to
exist in the form of monohydrate, Hydrate A, Anhydride Crystals B,
Anhydride Crystals C, Anhydride Crystals D, Anhydride Crystals E,
Anhydride Crystals F, and Anhydride Crystals G, etc., all of which
may be employed in the formulation of the present invention. Among
these, monohydrate and Anhydride Crystals B are most
preferable.
(A-2) Step of Preparing a Sterile Vehicle for the Sterile Bulk
Aripiprazole
[0116] A vehicle for the sterile bulk aripiprazole is prepared by
uniformly dissolving the above-mentioned suspending agent, and
optionally a bulking agent or an isotonic agent, a buffer, and a pH
adjusting agent in water for injection, and sterilizing the
resulting vehicle solution.
[0117] The method for sterilizing the vehicle solution is not
limited, but is preferably filtration with a filter. The pore size
of the filter is preferably about 0.2 .mu.m.
(A-3) Step of Combining the Sterile Aripiprazole and the Sterile
Vehicle to form a Sterile Primary Suspension
[0118] The sterile bulk aripiprazole and the sterile vehicle are
aseptically mixed to form a sterile primary suspension. The aseptic
mixing process is not limited as long as it is a known aseptic
stirring technique, such as an aseptic mixing method using a
mechanical stirring device with a propeller. Conditions at the time
of mixing are not limited. For example, preferable stirring
conditions are such that powder particles are mixed in a vehicle
without foaming.
[0119] The concentration of the sterile bulk aripiprazole to be
dispersed in the sterile vehicle may be suitably selected from a
wide range, but generally is about 10 to 400 mg/ml, preferably 50
to 250 mg/ml, most preferably about 100 mg/ml.
[0120] The mixing procedure in step (A-3) may be performed under
ordinary pressure (atmospheric pressure) or increased pressure.
Unlike in Patent Document 3, there is no need to adopt vacuum or
reduced pressure conditions. Under increased pressure, generally,
the mixing procedure is preferably carried out at a gauge pressure
of about 0 to 0.3 MPa. Preferred temperature conditions in step
(A-3) is about 5 to 80.degree. C., particularly about 10 to
40.degree. C. Unlike in Patent Document 1, there is no need to
employ temperatures at or above the melting point of bulk
aripiprazole.
(B) Step of Subjecting the Sterile Primary Suspension to First
Pulverization Using a High Shear Pulverizing Machine (e.g., High
Shear Homomixer), a Dispersion Machine that Applies Shear Force to
a Material to be Processed, a Colloid Mill, an Ultrasonic
Dispersion Machine, or a High-Pressure Jet Type Emulsifying
Dispersion Machine (e.g., High-Pressure Homogenizer) to Form a
Sterile Secondary Suspension
[0121] The particle size of the aripiprazole is reduced to a
desired level by a first pulverization step. Examples of
pulverizing machines used in the first pulverization step include
those which can suitably produce particles having a target particle
size, such as a high shear pulverizing machine, a dispersion
machine that applies shear force to a material to be processed, a
colloid mill, an ultrasonic dispersion machine (pulverizing
machine), or a high-pressure jet type emulsifying dispersion
machine (e.g., high-pressure homogenizer). A high shear pulverizing
machine or a dispersion machine that applies shear force to a
material to be processed, are preferably used. As such high shear
pulverizing machines, e.g., a high shear homomixer, various
commercial products are available, such as "Clearmix" (trade name,
produced by M-Technique Co., Ltd.). However, they are not limited
as long as they are high shear pulverizing machines that are
air-tight and free of foaming.
[0122] Conditions under which pulverization is carried out using a
high shear homomixer may be such that a target particle size can be
suitably obtained. The target particle size may be such that the
flow path of a homogenizer used in the subsequent second
pulverization step is not clogged. Typical conditions may be such
that the mean particle size is reduced to about 5 to 100 .mu.m,
preferably 5 to 50 .mu.m.
[0123] In the first pulverization step, pulverization is preferably
carried out using the above-mentioned apparatus at a rotating blade
(rotor) circumferential speed of typically 5 to 50 m/s, preferably
10 to 40 m/s, and more preferably about 15 to 35 m/s. It is
particularly effective to operate a high shear pulverizing machine,
such as a high shear homomixer (e.g., those available under the
trade name of Clearmix), at such a circumferential speed. For
example, secondary suspensions with a mean particle size of 10 to
20 .mu.m were obtained from a primary suspension (4 L, laboratory
scale) subjected to a first pulverization using a Clearmix CLM-1.5S
at a circumferential speed of 28.3 m/s, as well as from primary
suspensions (40 L, scale-up) subjected to a first pulverization
using a Clearmix CLM-9S or Clearmix CLM-15S at a circumferential
speed of 28.3 m/s.
[0124] Temperature conditions in step (B) are about 5 to 80.degree.
C., particularly about 10 to 40.degree. C.
[0125] In place of the high shear homomixer, a dispersion machine
that applies shear force to a material to be dispersed, namely, a
dispersion apparatus that exerts shear force to aripiprazole
particles during processing, can be used. Various commercial
products are available as such dispersion machines, including a
dispersion machine that applies shear force to a material to be
processed (trade name: "T-50 Basic" produced by IKA Japan, Inc.).
Conditions for pulverization by these dispersion machines may be
such that a target particle size can be suitably obtained. The
target particle size may be such that the flow path of a
homogenizer used in the subsequent second pulverization step is not
clogged. Typical conditions may be such that the mean particle size
is reduced to about 5 to 100 .mu.m, preferably 5 to 50 .mu.m.
[0126] Colloid mills, ultrasonic dispersion machine (pulverizing
machine) or high-pressure jet type emulsifying dispersion machines
may also be used under substantially the same conditions as
mentioned above.
[0127] The pulverization in step (B) may be conducted under
ordinary pressure (atmospheric pressure) or increased pressure.
Unlike in Patent Document 3, there is no need to adopt vacuum or
reduced pressure conditions. Under increased pressure, generally,
the mixing procedure is preferably carried out at a gauge pressure
of about 0 to 0.3 MPa.
(C) Step of Subjecting the Sterile Secondary Suspension to Second
Pulverization Using a High-Pressure Jet Type Emulsifying Dispersion
Machine (e.g., High-Pressure Homogenizer) to Form a Sterile Final
Suspension
[0128] The particle size of the aripiprazole is reduced to a
desired level by a second pulverization step. Examples of
pulverizing machines used in the second pulverization step include
a high-pressure jet type emulsifying dispersion machine that treats
process liquids under high pressure. A preferred high-pressure jet
type emulsifying dispersion machine is a high-pressure homogenizer
in which pump-pressurized process liquid is ejected as a jet-stream
at high pressure by adjusting a specially designed valve in an
ejecting section. Typical models of this type include EmulsiFlex
(produced by Avestin) and high-pressure homogenizers produced by
APV, NIRO SOAVI, or Sanwa Machine Co., Inc. Other dispersion
machines can also be used in which process liquids are passed at
high pressure through orifices of various shapes arranged in such a
direction that the process liquids collide with each other. Typical
models of this type include Microfluidizer (produced by
Microfluidics), Starburst (Sugino Machine Ltd.), and Nanomizer
(Yoshida Kikai Co., Ltd.), etc.
[0129] The pulverization pressure of the high-pressure homogenizer
is preferably about 300 to 1000 bar, more preferably about 300 to
600 bar. The inlet temperature of the high-pressure homogenizer may
be suitably selected from a wide range, but is generally about 1 to
70.degree. C., preferably about 5 to 40.degree. C.
[0130] By carrying out the second pulverization step under the
above conditions, the mean particle size of the aripiprazole in the
final suspension is preferably adjusted to about 1 to 10 .mu.m,
preferably 1 to 5 .mu.m, more preferably 2 to 4 .mu.m, most
preferably 2 to 3 .mu.m. The aripiprazole suspension having a mean
particle size of 2 to 3 .mu.m is useful because it has an excellent
absorption profile and undergoes no sedimentation during
manufacturing process.
[0131] The second pulverization step of step (C) may be carried out
by passing the suspension through a high-pressure homogenizer
plural times. In such a case, discrete-pass method and
recirculation method may be employed, giving similar results (see
Examples 1-5 and Example 6 described later). Both systems may also
be combined (see Example 7, described later).
[0132] The discrete-pass method specifically refers to a method in
which a suspension is processed by passing portions of the
suspension through, for example, a high-pressure homogenizer until
all portions thereof are processed while recovering the processed
suspension. When the suspension is processed plural times by
discrete-pass method, the recovered suspension is processed by
passing portions of the recovered suspension through a
high-pressure homogenizer until all portions thereof are processed
while recovering the processed suspension, and this procedure is
repeated.
[0133] The recirculation method specifically refers to a method in
which a tank or vessel containing a suspension, connected to the
inlet of, e.g., a high-pressure homogenizer, is also connected to
the outlet of the homogenizer via a recycle line, and the
suspension in the tank or vessel is continuously processed by the
homogenizer, without being recovered, so that the processed
suspension is recycled through the recycle line to the tank or
vessel where it is mixed with unprocessed suspension, and the
mixture is continuously passed through the homogenizer, and thus
the suspension is processed with recirculation.
[0134] The pulverization in step (C) does not require vacuum or
reduced pressure conditions, unlike in Patent Document 3.
[0135] When a high-pressure homogenizer is used in both the first
and second pulverization steps, steps (B) and (C) of the production
method comprising the above-mentioned steps (A) to (C) of the
invention are preferably carried out as shown in the following
steps (BB) and (CC), respectively.
Step (BB)
[0136] Step (BB) of the invention is a first pulverization step in
which the sterile primary suspension obtained in step (A) is
pulverized using a high-pressure homogenizer at a pulverization
pressure of 50 to 200 bar, preferably 70 to 150 bar, to obtain a
secondary suspension. It was found that this step, when adopted,
solves the clogging problem mentioned above.
[0137] In other words, the use of the high-pressure homogenizer at
a pulverization pressure within the range of 50 to 200 bar,
preferably 70 to 150 bar, prevents the clogging of the flow path of
the high-pressure homogenizer.
[0138] The inlet temperature of the high-pressure homogenizer may
be suitably selected from a wide range, but generally is about 1 to
50.degree. C., preferably about 5 to 40.degree. C.
[0139] A sterile secondary suspension is obtained in this
manner.
Step (CC)
[0140] Step (CC) of the invention is a second pulverization step in
which the sterile secondary suspension obtained in step (BB) is
pulverized using a high-pressure homogenizer at a pulverization
pressure of 200 to 1000 bar to obtain a sterile final suspension.
This step provides an aripiprazole suspension having the desired
mean particle size of 1 to 10 .mu.m, preferably 1 to 5 .mu.m, more
preferably 2 to 4 .mu.m, most preferably about 2.5 .mu.m.
[0141] In step (CC), the pulverization pressure of the
high-pressure homogenizer needs to be increased, compared with the
pulverization pressure in step (BB). Generally, the pulverization
pressure in step (CC) is preferably set higher than that of step
(BB) by about 100 to 900 bar, particularly about 200 to 500
bar.
[0142] Preferred pulverization pressure of the high-pressure
homogenizer in step (CC) is 200 to 1000 bar, particularly about 300
to 600 bar.
[0143] Also, when the pulverization is carried out plural times in
step (CC), the pulverization pressure can be increased stepwise
within the range of 200 to 1000 bar. In this case, the final
pressure is preferably about 300 to 1000 bar, more preferably about
300 to 600 bar.
[0144] The inlet temperature of the high-pressure homogenizer is
suitably selected from a wide range, but is generally about 1 to
50.degree. C., preferably about 5 to 40.degree. C.
[0145] The second pulverization step of step (CC) may be carried
out by passing the suspension through a high-pressure homogenizer
plural times. The discrete-pass method and a recirculation method
mentioned above may be employed, giving similar results. Both
methods may also be combined.
[0146] The pulverization in step (CC) does not require vacuum or
reduced pressure conditions, unlike in Patent Document 3.
[0147] In the invention, it is possible to perform cleaning and
sterilization of the surfaces that are exposed to liquids, of the
machines used in the invention, such as a high shear pulverizing
machine, a dispersion machine that applies shear force to a
material to be processed, a colloid mill, an ultrasonic dispersion
machine, and a high-pressure jet type emulsifying dispersion
machine, by conducting clean-in-place (CIP) and
sterilization-in-place (SIP). In-line sterilization is also
possible. CIP may be carried out using water, hot water, alkaline
water, acidic water, or organic solvent, with optional addition of
one or more cleaning agents conventionally used, such as alkaline
detergents, neutral detergents and acidic detergents. SIP may be
carried out using pure steam, high pressure high temperature water,
etc.
[0148] Thus, a sterile aripiprazole suspension wherein the
aripiprazole has a mean particle size of 1 to 10 .mu.m is obtained
by aseptically pulverizing, in step (b), a sterile primary
aripiprazole suspension produced in step (a) using a high shear
pulverizing machine (such as, a high-shear homomixer), a dispersion
machine that applies shear force to a material to be processed, a
colloid mill, an ultrasonic dispersion machine, or a high-pressure
jet type emulsifying dispersion machine (such as a high-pressure
homogenizer), whose surfaces exposed to liquids have been
sterilized, to form a sterile secondary suspension, and aseptically
pulverizing the resulting sterile secondary suspension in step (c)
using a high-pressure jet type emulsifying dispersion machine (such
as a high-pressure homogenizer), whose surfaces exposed to liquids
have been sterilized.
Aripiprazole Aqueous Suspension
[0149] The aripiprazole in the aripiprazole aqueous suspension
produced by the production method of the invention has a mean
particle size of 1 to 10 .mu.m, preferably 1 to 5 .mu.m, more
preferably 2 to 4 .mu.m, most preferably about 2 to 3 .mu.m.
[0150] According to the production method of the invention, no
matter how large the mean particle size of bulk aripiprazole is,
the mean particle size of aripiprazole in the suspension finally
obtained is controlled within the above range. Therefore, the
method has great advantages: there are few restrictions in the
production of sterile bulk poweder; when using bulk powder with a
large particle size, air bubble entrainment rarely occurs during
preparation of the suspension, and the defoaming process is easy;
there is no need for reduced pressure, and the possibility of
contamination from outside air is significantly decreased.
[0151] According to the production method of the invention, a
homogeneous final suspension free of coarse aripiprazole particles
can be produced, and therefore, the final suspension obtained
(namely, the desired aripiprazole suspension) may be filtered for
removing foreign substances, if so desired. The filter to be used
has a pore size such that the filter has a nominal filtration
rating of 10 to 225 .mu.m, preferably 20 to 70 .mu.m. Therefore,
the production method of the invention may further comprise the
step of filtering the final suspension obtained in step (c) with a
filter having a nominal filtration rating of 10 to 225 .mu.m.
[0152] The resulting final suspension (namely, the desired
aripiprazole suspension) preferably has an aripiprazole
concentration of about 10 to 400 mg/ml, more preferably about 50 to
250 mg/ml, most preferably 100 mg/ml.
[0153] The sterile aripiprazole suspension obtained by the
production method of the invention is administered, for example,
intramuscularly and subcutaneously, as formulation for
injection.
Method for Producing Freeze-Dried Formulation
[0154] The sterile aripiprazole suspension obtained by the
aforementioned method may be freeze-dried to produce a freeze-dried
formulation.
[0155] More specifically, the final aripiprazole suspension may be
freeze-dried into a freeze-dried formulation of a desired
polymorphic form (an anhydrate, Hydrate A, or a mixture of them).
To obtain a freeze-dried formulation of Aripiprazole Hydrate A, a
monohydrate or Hydrate A is used as bulk aripiprazole, and the
Hydrate A suspension obtained by the method of the invention is
subjected to the following freeze-drying cycle.
[0156] The freeze-drying cycle comprises cooling the suspension to
-20.degree. C. to -55.degree. C. at a suitable cooling rate to
freeze the suspension, and performing a drying step at a
temperature below around 0.degree. C. (preferably around 0.degree.
C. to -15.degree. C.) under a suitable vacuum (e.g. about 1 to 100
Pa) and for a suitable duration (e.g. until the freeze-dried
formulation is obtained; typically for about 10 to 100 hours).
[0157] If a freeze-dried formulation containing aripiprazole in
anhydrous form is desired, aripiprazole in the form of a
monohydrate or anhydrous crystals is used as the bulk aripiprazole,
and the suspension obtained by the method of the invention is
subjected to the following freeze-drying cycle. The freeze-drying
cycle comprises the three steps (freezing, primary drying,
secondary drying). Specifically, the freeze-drying cycle comprises
cooling the suspension to -20.degree. C. to -55.degree. C. at a
suitable cooling rate to freeze the suspension; performing primary
drying at a temperature below around 0.degree. C. (preferably
around 0.degree. C. to -20.degree. C.) under a suitable vacuum
(e.g. about 1 to 100 Pa) and for a suitable duration (typically for
about 10 to 100 hours); and performing secondary drying at a
temperature above around 0.degree. C. (preferably 0.degree. C. to
60.degree. C.) under a suitable vacuum (e.g. about 0.1 to 20 Pa)
and for a suitable duration (e.g. until the freeze-dried
formulation is obtained; typically for about 10 to 100 hours).
[0158] The freeze-dried formulation thus produced can be easily
reconstituted into a desired aripiprazole suspension using water
for injection immediately before the administration. Therefore, the
freeze-dried formulation is useful as a formulation immediately
prepared before use. Even by a reconstitution method as simple as
adding water for injection to the formulation and shaking the
mixture by hand, a homogeneous aripiprazole suspension can be
obtained.
EXAMPLES
[0159] Examples are provided below to describe the present
invention in further detail.
[0160] In each example, the mean particle size is the volume mean
diameter measured with a laser-light scattering (LLS) diffraction
particle size analyzer (laser diffraction particle size analyzer
SALD-3000J, Shimadzu Corp.). The terms "10% diameter", "50%
diameter", and "90% diameter" refer to, in particle size
distribution, the particle diameter of the point where the
distribution curve of integration (%) intersects with 10% value of
the integrated value, the particle diameter of the point at the
intersection with 50% value, and the particle diameter of the point
at the intersection with 90% value, respectively. Measurement
conditions are as follows. Medium: water; refractive index: 2.00 to
0.20i; cell: flow cell.
[0161] In each example, both steps of preparing a vehicle and
combining bulk aripiprazole and the vehicle to form a primary
suspension were carried out at room temperature (20 to 30.degree.
C.), unless otherwise specified. The first pulverization step for
pulverizing the primary suspension was carried out at 20 to
45.degree. C., unless otherwise specified.
[0162] The high-pressure homogenizer used in each example is a
commercially available high-pressure homogenizer (trade name "PANDA
2K Type", manufactured by NIRO SOAVI).
Example 1
[0163] (a) Sodium carboxymethyl cellulose (18.30 g), 91.52 g of
mannitol, and 1.63 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 2059.2 g.
The solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution, and filtered through a 0.2 .mu.m filter.
[0164] In the resulting filtrate (1872 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=258 .mu.m; 10% diameter=99 .mu.m; 50%
diameter=280 .mu.m; 90% diameter=609 .mu.m) was dispersed to form a
primary suspension.
[0165] The dispersion procedure for preparing the primary
suspension was conducted by using a Three-One Motor (produced by
HEIDON) for stirring with 100 mm-diameter blades at about 200 to
400 rpm. (The same applies to the following examples, unless
otherwise noted.)
[0166] (b) The primary suspension was pulverized with a high shear
homomixer (trade name: "Clearmix (CLM-1.5S)", produced by M
Technique Co., Ltd.) at 18000 rpm for 7.5 minutes per liter. As a
result, a secondary suspension was obtained.
[0167] (c) The obtained secondary suspension was cooled or warned
so as to keep the inlet temperature at about 10.degree. C., about
20.degree. C., about 40.degree. C., and about 60.degree. C. The
suspension was pulverized by passing 10 times through a
high-pressure homogenizer at 600 bar by discrete-pass method.
[0168] The mean particle size of the suspensions pulverized once
and pulverized 10 times was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.). The results are
shown below.
TABLE-US-00001 TABLE 1 Number of Times Mean Particle Size (.mu.m)
Pulverized 10.degree. C. 20.degree. C. 40.degree. C. 60.degree. C.
1 5.1 5.0 4.5 4.9 10 1.8 1.9 2.3 3.9
[0169] Table 1 reveals the following:
[0170] (i) Even when bulk aripiprazole monohydrate produced by
batch crystallization was used, passing the suspension once through
a high-pressure homogenizer at 600 bar at an inlet temperature of
10 to 60.degree. C. in the second pulverization (step (c))
permitted the preparation of an aripiprazole suspension with a mean
particle size of 1 to 10 .mu.m.
[0171] (ii) Passing the suspension 10 times through a high-pressure
homogenizer at 600 bar at an inlet temperature of 10 to 60.degree.
C. in the second pulverization (step (c)) enabled the preparation
of an aripiprazole suspension with a mean particle size of about 2
to 4 .mu.m.
[0172] (iii) Passing the suspension 10 times through a
high-pressure homogenizer at 600 bar at an inlet temperature of 10
to 40.degree. C. in the second pulverization (step (c)) allowed the
preparation of an aripiprazole suspension with a mean particle size
of about 2 to 3 .mu.m.
[0173] This shows that a suspension with the desired mean particle
size (1-10 .mu.m, preferably 1-5 .mu.m, more preferably 2 to 4
.mu.m) is obtained even by the use of bulk powder with a large mean
particle size, which is one of the effects of the present
invention.
[0174] The same results as above are obtained even using sterile
bulk aripiprazole and a sterile vehicle. The same applies to the
following examples.
Example 2
[0175] Sodium carboxymethyl cellulose (45.76 g), 228.80 g of
mannitol, and 4.07 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 5148 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution, and filtered through a 0.2 .mu.m filter.
[0176] In the resulting filtrate (1872 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=239 .mu.m; 10% diameter=99 .mu.m; 50%
diameter=276 .mu.m; 90% diameter=632 .mu.m) was dispersed to form a
primary suspension.
[0177] The primary suspension was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0178] The obtained secondary suspension was cooled so as to keep
the inlet temperature at about 20.degree. C., and pulverized by
passing 10 times through a high-pressure homogenizer at 300 bar,
600 bar, and 1000 bar by discrete-pass method. The mean particle
size of the suspensions pulverized once and pulverized 10 times was
measured with a particle size distribution analyzer (SALD-3000J,
Shimadzu Corp.). The results are shown below.
TABLE-US-00002 TABLE 2 Number of Times Mean Particle Size (.mu.m)
Pulverized 300 bar 600 bar 1000 bar 1 5.7 4.5 4.3 10 2.6 1.9
2.5
Table 2 indicates the following:
[0179] (i) Even when bulk aripiprazole monohydrate produced by
batch crystallization was used, passing the suspension once though
a high-pressure homogenizer at 300 to 1000 bar enabled the
preparation of an aripiprazole suspension with a mean particle size
of 1 to 10 .mu.m.
[0180] (ii) Passing the suspension 10 times though a high-pressure
homogenizer at 300 to 1000 bar allowed the preparation of an
aripiprazole suspension with a mean particle size of 2 to 3
.mu.m.
[0181] (iii) The preparation of an aripiprazole suspension with a
mean particle size of 2 to 3 .mu.m is also possible at 1000 bar.
However, the desired aripiprazole suspension can be efficiently
obtained at 300 to 600 bar.
Example 3
[0182] Sodium carboxymethyl cellulose (45.76 g), 228.80 g of
mannitol, and 4.07 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 5148 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
solution and filtered through a 0.2 .mu.m filter. Two kinds of
sodium carboxymethyl cellulose with a viscosity of 93 cps (4%
aqueous solution, 25.degree. C.) and 187 cps (4% aqueous solution,
25.degree. C.) were used.
[0183] In the resulting filtrate (1872 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder used for studying sodium carboxymethyl
cellulose with a viscosity of 93 cps=258 .mu.m; 10% diameter=99
.mu.m; 50% diameter=280 .mu.m; 90% diameter=609 .mu.m; mean
particle size of the bulk powder used for studying sodium
carboxymethyl cellulose with a viscosity of 187 cps=239 .mu.m; 10%
diameter=99 .mu.m; 50% diameter=276 .mu.m; 90% diameter=632 .mu.m)
was dispersed to form primary suspensions.
[0184] Each of the primary suspensions was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result,
secondary suspensions were obtained.
[0185] The obtained secondary suspensions were cooled so as to keep
the inlet temperature at about 20.degree. C., and pulverized by
passing 10 times through a high-pressure homogenizer at 600 bar by
discrete-pass method. The mean particle size of the suspensions
pulverized once and pulverized 10 times was measured with a
particle size distribution analyzer (SAID-3000J, Shimadzu Corp.).
The results are shown below.
TABLE-US-00003 TABLE 3 Mean Particle Size (.mu.m) Viscosity of
Sodium Carboxymethyl Number of Times Cellulose Pulverized 93 cps
187 cps 1 5.0 4.5 10 1.9 1.9
[0186] Table 3 indicates that the difference in viscosity of CMCNa
does not influence the pulverization.
Example 4
[0187] Sodium carboxymethyl cellulose (33.28 g), 166.40 g of
mannitol, and 2.96 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 3744 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0188] In the resulting filtrate (1872 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=386 .mu.m; 10% diameter=118 .mu.m; 50%
diameter=356 .mu.m; 90% diameter=1640 .mu.m) was dispersed to form
a primary suspension. The dispersion procedure for preparing the
primary suspension was conducted by using a Three-One Motor
(produced by HEIDON) for stirring with 50 mm-diameter blades at
about 700 to 800 rpm.
[0189] The primary suspension was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0190] Without temperature control, the obtained secondary
suspension was pulverized by passing 10 times through a
high-pressure homogenizer at 600 bar by discrete-pass method. The
mean particle size of the suspensions pulverized once and
pulverized 10 times was measured with a particle size distribution
analyzer (SALD-3000J, Shimadzu Corp.). The results are shown
below.
TABLE-US-00004 TABLE 4 Number of Times Mean Particle Size
Pulverized (.mu.m) 1 5.0 10 3.0
[0191] Table 4 shows that even without controlling the inlet
temperature, an aripiprazole suspension with a mean particle size
of about 3 to 5 .mu.m can be prepared. When controlling the inlet
temperature, an aripiprazole suspension with a mean particle size
of less than 3 microns can be obtained (see Examples 1 and 2).
Example 5
[0192] Sodium carboxymethyl cellulose (45.76 g), 228.80 g of
mannitol, and 4.07 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 5148 g.
Sodium carboxymethyl cellulose with a viscosity of 93 cps (4%
aqueous solution, 25.degree. C.) and 187 cps (4% aqueous solution,
25.degree. C.) were used for preparation. The solution was adjusted
to pH 7.0 with a 1 mol/L sodium hydroxide solution and filtered
through a 0.2 .mu.m filter.
[0193] In the resulting filtrate (1872 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=239 .mu.m; 10% diameter=99 .mu.m; 50%
diameter=276 .mu.m; 90% diameter=632 .mu.m) was dispersed to form
primary suspensions.
[0194] The primary suspensions were pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result,
secondary suspensions were obtained.
[0195] The obtained secondary suspensions were cooled so as to keep
the inlet temperature at about 20.degree. C., and pulverized by
passing 10 times through a high-pressure homogenizer at 300 bar by
discrete-pass method.
[0196] The mean particle size of the suspensions pulverized once
and pulverized 10 times was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.). The results are
shown below.
TABLE-US-00005 TABLE 5 Mean Particle Size (.mu.m) Viscosity of
Sodium Carboxymethyl Number of Times Cellulose Pulverized 93 cps
187 cps 1 5.3 5.7 10 2.5 2.6
[0197] Table 5 reveals that in the second pulverization step, even
though the pulverization pressure of the high-pressure homogenizer
is 300 bar, the difference in CMCNa viscosity does not affect the
pulverization, as in Example 3.
Example 6
[0198] Sodium carboxymethyl cellulose (183 g), 915 g of mannitol,
and 16.3 g of sodium dihydrogen phosphate monohydrate were
dissolved in purified water. The total weight was 20592 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0199] In the resulting filtrate (18720 g), bulk aripiprazole
monohydrate produced by batch crystallization (2080 g; mean
particle size of the bulk powder=246 .mu.m; 10% diameter=103 .mu.m;
50% diameter=260 .mu.m; 90% diameter=548 .mu.m) was dispersed to
form a primary suspension.
[0200] The primary suspension was pulverized with Clearmix (CLM-9S)
at 5700 rpm for 2.1 minutes per liter. As a result, a secondary
suspension was obtained.
[0201] The obtained secondary suspension (500 mL) was recirculated
through a high-pressure homogenizer, and cooled at the outlet of
the high-pressure homogenizer to adjust the inlet temperature at
about 15.degree. C. to about 25.degree. C. The suspension was
pulverized for 32.5 minutes at a pulverization pressure of 500 bar,
while being discharged from the high-pressure homogenizer at a rate
of 155 mL/min.
[0202] The mean particle size of the suspensions pulverized for
3.25 minutes and 32.5 minutes was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.). The results are
shown below.
TABLE-US-00006 TABLE 6 Pulverization Time Mean Particle Size
(Minutes) (.mu.m) 3.25 3.5 32.5 1.7
[0203] Table 6 shows that the desired pulverization is also
possible by recirculation method, like pulverization by
discrete-pass method as used in Examples 1 to 5. Additionally, it
is seen that even when the pulverization by recirculation method is
repeatedly performed over a long time, the mean particle size do
not fall below 1 .mu.m.
Example 7
[0204] Sodium carboxymethyl cellulose (45.76 g), 228.80 g of
mannitol, and 4.07 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 5148 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0205] In the resulting filtrate (1872 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=256 .mu.m; 10% diameter=109 .mu.m; 50%
diameter=272 .mu.m; 90% diameter=566 .mu.m) was dispersed to form a
primary suspension.
[0206] The primary suspension was pulverized using Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0207] The obtained secondary suspension (500mL) was cooled so as
to keep the inlet temperature at about 20.degree. C., and
pulverized by passing four times through a high-pressure
homogenizer at 500 bar. Subsequently, the suspension was circulated
through a high-pressure homogenizer, and cooled at the outlet of
the high-pressure homogenizer to adjust the inlet temperature at
about 20.degree. C. The suspension was further pulverized by
recirculation method for 42 minutes at a pulverization pressure of
500 bar, while being discharged at a rate of 155 mL/min.
[0208] The mean particle size of the suspensions pulverized once,
pulverized four times by discrete-pass method, and pulverized four
times by discrete-pass method and further pulverized for 42 minutes
by recirculation method was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.). The results are
shown below.
TABLE-US-00007 TABLE 7 Number of Times Pulverized, or Mean Particle
Size Pulverization Time (.mu.m) 1 4.0 4 2.6 42 Minutes after Four-
1.6 Time Pulverization.sup.1) .sup.1)The suspension was pulverized
four times by discrete-pass method and further pulverized for 42
minutes by recirculation method.
[0209] Table 7 shows that the discrete-pass method may be combined
with the recirculation method. Moreover, even when the
recirculation pulverization is repeatedly performed over a long
time, the mean particle size do not fall below 1 .mu.m.
Example 8
[0210] Sodium carboxymethyl cellulose (450 g), 2250 g of mannitol,
40 g of sodium dihydrogen phosphate monohydrate, and 160 g of a 1
mol/L sodium hydroxide aqueous solution were dissolved in purified
water. The total weight was 50625 g. The solution was filtered
through a 0.2 .mu.m filter. In the filtrate (748.8 g), bulk
aripiprazole monohydrate produced by batch crystallization (83.2 g;
mean particle size of the bulk powder=256 .mu.m; 10% diameter=109
.mu.m; 50% diameter=272 .mu.m; 90% diameter=566 .mu.m) was
dispersed to form a primary suspension.
[0211] The primary suspension was pulverized with a dispersion
machine that applies shear force to a material to be processed
(trade name: "T-50 Basic", produced by IKA Japan, Inc.) using a
shaft available under the generic name of shaft generator (trade
name: "S50N-G45G", produced by IKA Japan, Inc.) at 6400 rpm for 7.5
minutes per liter. As a result, a secondary suspension was
obtained.
[0212] The obtained secondary suspension was cooled so as to keep
the inlet temperature at about 20.degree. C., and pulverized five
times in total by passing through a high-pressure homogenizer once
at 300 bar and four times at 500 bar by discrete-pass method. The
mean particle size of the suspensions pulverized once and
pulverized five times was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.). The results are
shown below.
TABLE-US-00008 TABLE 8 Number of Times Mean Particle Size
Pulverized (.mu.m) 1 6.4 5 2.7
[0213] Table 8 indicates that any pulverizing machines may be used
for the first pulverization as long as they have some degree of
shear force to pulverize bulk powder. Not only the aforementioned
high shear homomixers (e.g., Clearmix) but also dispersion machines
(e.g., "T-50 Basic", produced by IKA Japan, Inc.) are usable.
Example 9
[0214] Sodium carboxymethyl cellulose (450 g), 2250 g of mannitol,
40 g of sodium dihydrogen phosphate monohydrate, and 160 g of a 1
mol/L sodium hydroxide aqueous solution were dissolved in purified
water. The total weight was 50625 g. The solution was filtered
through a 0.2 .mu.m filter. In the filtrate (748.8 g), bulk
aripiprazole monohydrate produced by batch crystallization (83.2 g;
mean particle size of the bulk powder=256 .mu.m; 10% diameter =109
.mu.m; 50% diameter=272 .mu.m; 90% diameter=566 .mu.m) was
dispersed to form a primary suspension.
[0215] The primary suspension was cooled so as to keep the inlet
temperature at about 20.degree. C., and pulverized six times in
total by discrete-pass method by passing through a high-pressure
homogenizer once at 100 bar (first pulverization step), and once at
300 bar and four times at 500 bar (second pulverization step). The
mean particle size of the suspensions pulverized once, pulverized
twice, and pulverized six times was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.).
The results are shown below.
TABLE-US-00009 TABLE 9 Number of Times Mean Particle Size
Pulverized (.mu.m) 1 18.6 2 4.7 6 2.4
[0216] Table 9 shows that even a high-pressure homogenizer can be
used for the first pulverization step without inducing clogging in
the line, if a lower pulverization pressure is used.
Example 10
[0217] Sodium carboxymethyl cellulose (16.64 g), 83.20 g of
mannitol, and 1.48 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 3704 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0218] In the resulting filtrate (1852 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=238 .mu.m; 10% diameter=72 .mu.m; 50%
diameter=274 .mu.m; 90% diameter=811 .mu.m) was dispersed to form a
primary suspension.
[0219] The primary suspension was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0220] Without temperature control, the obtained secondary
suspension was pulverized by passing 10 times through a
high-pressure homogenizer at 600 bar by discrete-pass method. The
mean particle size of the suspensions pulverized once and
pulverized 10 times was measured with a particle size distribution
analyzer (SALD-3000J, Shimadzu Corp.). The results are shown
below.
TABLE-US-00010 TABLE 10 Number of Times Mean Particle Size
Pulverized (.mu.m) 1 4.5 10 3.4
[0221] Table 10 indicates that even without controlling the inlet
temperature, an aripiprazole suspension with a mean particle size
of about 3 to 5 .mu.m can be prepared. When controlling the inlet
temperature, an aripiprazole suspension with a mean particle size
of less than 3 microns can be obtained (see Example 11 below).
Example 11
[0222] Sodium carboxymethyl cellulose (16.64 g), 83.20 g of
mannitol, and 1.48 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 3704 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0223] In the resulting filtrate (1852 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=238 .mu.m; 10% diameter=72 .mu.m; 50%
diameter=274 .mu.m; 90% diameter=811 .mu.m) was dispersed to form a
primary suspension.
[0224] The primary suspension was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0225] The obtained secondary suspension was cooled so as to keep
the inlet temperature at about 20.degree. C., and pulverized by
passing 10 times through a high-pressure homogenizer at 600 bar by
discrete-pass method.
[0226] The mean particle size of the suspensions pulverized once
and pulverized 10 times was measured with a particle size
distribution analyzer (SALD-3000J, Shimadzu Corp.). The results are
shown below.
TABLE-US-00011 TABLE 11 Number of Times Mean Particle Size
Pulverized (.mu.m) 1 4.6 10 1.9
[0227] Table 11 indicates that even when the concentration of CMCNa
as a suspending agent is low, first pass allows the preparation of
a suspension with a mean particle size of 1 to 5 .mu.m, and 10-time
passing allows the preparation of a suspension with a mean particle
size of 2 .mu.m.
Example 12
[0228] Sodium carboxymethyl cellulose (16.64 g), 83.20 g of
mannitol, and 1.48 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 3704 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0229] In the resulting filtrate (1852 g), bulk aripiprazole
monohydrate produced by batch crystallization (208 g; mean particle
size of the bulk powder=258 .mu.m; 10% diameter=99 .mu.m; 50%
diameter=280 .mu.m; 90% diameter=609 .mu.m) was dispersed to form a
primary suspension.
[0230] The primary suspension was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0231] The obtained secondary suspension was cooled or warmed so as
to keep the inlet temperature at about 10.degree. C., about
20.degree. C., about 40.degree. C., and about 60.degree. C., and
pulverized by passing 10 times through a high-pressure homogenizer
at 600 bar by discrete-pass method. The mean particle size of the
suspensions pulverized once and pulverized 10 times was measured
with a particle size distribution analyzer (SALD-3000J, Shimadzu
Corp.). The results are shown below.
TABLE-US-00012 TABLE 12 Number of Times Mean Particle Size (.mu.m)
Pulverized 10.degree. C. 20.degree. C. 40.degree. C. 60.degree. C.
1 4.6 4.4 4.5 4.7 10 1.8 2.1 2.3 4.2
[0232] Table 12 indicates the following:
[0233] (i) Even when the concentration of CMCNa is low, a
suspension with a mean particle size of 1 to 5 .mu.m can be
prepared as in Example 1.
[0234] (ii) Even when the concentration of CMCNa is low, a
suspension with a mean particle size of 2 to 3 .mu.m can be
prepared as in Example 1, by adjusting the inlet temperature to
40.degree. C. or less.
Example 13
[0235] Sodium carboxymethyl cellulose (8.32 g), 41.60 g of
mannitol, and 0.74 g of sodium dihydrogen phosphate monohydrate
were dissolved in purified water. The total weight was 1852 g. The
solution was adjusted to pH 7.0 with a 1 mol/L sodium hydroxide
aqueous solution and filtered through a 0.2 .mu.m filter.
[0236] In the obtained filtrate (740.8 g), bulk aripiprazole
monohydrate produced by batch crystallization (83.2 g; mean
particle size of the bulk powder=256 .mu.m; 10% diameter=99 .mu.m;
50% diameter=280 .mu.m; 90% diameter=609 .mu.m) was dispersed to
form a primary suspension. The dispersion procedure for preparing
the primary suspension was conducted by using Three One Motor
(produced by HEIDON) for stirring with 50 mm-diameter blades at
about 300 to 500 rpm.
[0237] The primary suspension was pulverized with Clearmix
(CLM-1.5S) at 18000 rpm for 7.5 minutes per liter. As a result, a
secondary suspension was obtained.
[0238] The obtained secondary suspension (450 mL) was circulated
through a high-pressure homogenizer, and cooled at the outlet of
the high-pressure homogenizer to adjust the inlet temperature at
about 20.degree. C.
[0239] The suspension was pulverized by recirculation method for
72.5 minutes at a pulverization pressure of 500 bar, while being
discharged from the high-pressure homogenizer at a rate of 155
mL/min. The mean particle size of the suspensions pulverized for
14.5 minutes and pulverized for 72.5 minutes was measured with a
particle size distribution analyzer (SAID-3000J, Shimadzu Corp.).
The results are shown below.
TABLE-US-00013 TABLE 13 Pulverization Time Mean Particle Size
(Minutes) (.mu.m) 14.5 2.2 72.5 1.5
[0240] Table 13 shows that even though the concentration of CMCNa
is low, the desired pulverization is possible by recirculation
method; additionally, even when the recirculation pulverization is
repeatedly performed over a long time, the mean particle size do
not fall below 1 .mu.m.
Example 14
[0241] Each of aripiprazole suspensions obtained by the method
shown in Examples 1 to 13 (2.5 mL) was poured into a glass vial,
and the vial was partially stoppered with a rubber stopper. The
vials were transferred to a freeze-dryer and lyophilized under the
following conditions:
[0242] (a) Freezing: The vials were cooled to -40.degree. C. at
1.degree. C./min., and then kept at -0.degree. C. for 6 hours;
[0243] (b) Drying: The chamber pressure was lowered to about 13 Pa,
and the shelf temperature of the freeze-dryer was increased to
-5.degree. C. at a rate of 0.3.degree. C./min.; drying was then
continued for 55.5 hours while the degree of vacuum was kept at
about 13 Pa, and the shelf temperature kept at about -5.degree.
C.;
[0244] (c) The vials were stoppered under atmospheric pressure or
partial vacuum using nitrogen or air, and then removed from the
freeze-dryer; and
[0245] (d) The vials were sealed with aluminum seals.
[0246] The aripiprazole each of the resulting freeze-dried
aripiprazole suspensions was Hydrate A.
Example 15
[0247] Each of the aripiprazole suspensions obtained by the method
shown in Examples 1 to 13 was poured into a glass vial, and the
vial was partially stoppered with a rubber stopper. The vials were
transferred to a freeze-dryer and lyophilized under the following
conditions:
[0248] (a) Freezing: The vials were cooled to -40.degree. C. at
1.degree. C./min., and then kept at -40.degree. C. for 6 hours;
[0249] (b) Primary drying: The chamber pressure was lowered to
about 13 Pa, and the shelf temperature of the freeze-dryer was
increased to -5.degree. C. at a rate of 0.3.degree. C./min.;
primary drying was then continued for 55.5 hours while the degree
of vacuum was kept at about 13 Pa, and the shelf temperature kept
at about -5.degree. C.;
[0250] (c) Secondary drying: The shelf temperature was increased to
25.degree. C., and drying continued for 24 hours while the degree
of vacuum was kept at about 13 Pa; the shelf temperature was then
increased to 50.degree. C., and drying continued for 24 hours while
the degree of vacuum was kept at about 13 Pa;
[0251] (d) The vials were stoppered under atmospheric pressure or
partial vacuum using nitrogen or air, and then removed from the
freeze-dryer; and
[0252] (e) The vials were sealed with aluminum seals. The
aripiprazole each of the resulting freeze-dried aripiprazole
suspensions was in the anhydrous form.
* * * * *